Provided by Tiger Trade Technology Pte. Ltd.

WAVE Life Sciences

16.34
-0.0700-0.43%
Post-market: 16.390.0500+0.31%17:49 EST
Volume:4.76M
Turnover:78.07M
Market Cap:2.73B
PE:-21.98
High:17.14
Open:16.35
Low:16.01
Close:16.41
52wk High:21.73
52wk Low:5.28
Shares:167.00M
Float Shares:96.81M
Volume Ratio:0.45
T/O Rate:4.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7436
EPS(LYR):-0.7015
ROE:-86.51%
ROA:-28.33%
PB:21.91
PE(LYR):-23.29

Loading ...

Wave Life Sciences Ltd - Further Clinical Data Updates Expected in 1Q 2026 for Wve-007

THOMSON REUTERS
·
Dec 08

Wave Life Sciences Ltd - Single 240 Mg Dose of Wve-007 Reduces Visceral Fat by 9.4%

THOMSON REUTERS
·
Dec 08

Wave Life Sciences Announces Positive Interim Data From Phase 1 Inlight Trial of Wve-007 (Inhbe) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to Glp-1 at Three Months Without Muscle Loss

THOMSON REUTERS
·
Dec 08

Wave Life Sciences Ltd - Wve-007 Generally Safe and Well Tolerated With Mild Adverse Events

THOMSON REUTERS
·
Dec 08

Wave Life Sciences Ltd - Phase 2 Trials Planned for Wve-007 as Monotherapy and Add-on

THOMSON REUTERS
·
Dec 08

Wave Life Sciences Announces Interim Data from Phase 1 INLIGHT Trial of Obesity Drug WVE-007

Reuters
·
Dec 08

Wave Life Sciences to Announce Interim Data From the Phase 1 Inlight Trial of Wve-007 (Inhbe) for Obesity on Monday, December 8, 2025

THOMSON REUTERS
·
Dec 08

Wave Life Sciences Releases Corporate Presentation Document

Reuters
·
Nov 17

RA Capital Management Reports Acquisition of Common Shares of Wave Life Sciences Ltd

Reuters
·
Nov 15

Wave Life Sciences (WVE): Assessing Valuation After Recent Volatility and Analyst Price Target Gap

Simply Wall St.
·
Nov 14

Stock Track | WAVE Life Sciences Surges 5.68% After Hours on Promising Obesity Treatment Results

Stock Track
·
Nov 13

Could Wave Life Sciences' (WVE) Novel Obesity Data Reveal a Strategic Shift in Its Pipeline Focus?

Simply Wall St.
·
Nov 13

Stock Track | WAVE Life Sciences Soars 5.04% Despite Mixed Q3 Results and Analyst Actions

Stock Track
·
Nov 12

These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results

Benzinga
·
Nov 12

Wave Life Sciences Is Maintained at Outperform by Wedbush

Dow Jones
·
Nov 11

Wedbush Raises Price Target on Wave Life Sciences to $20 From $18, Keeps Outperform Rating

MT Newswires Live
·
Nov 11

Wave Life Sciences price target lowered to $16 from $18 at Wells Fargo

TIPRANKS
·
Nov 11

Stock Track | WAVE Life Sciences Plummets 5.22% as Q3 Earnings Miss Estimates Across the Board

Stock Track
·
Nov 10

Stock Track | WAVE Life Sciences Plummets 5.22% as Q3 Results Miss Expectations

Stock Track
·
Nov 10

Wave Life Sciences Q3 revenue, profit miss expectations

Reuters
·
Nov 10